Codexis (CDXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, to be held virtually, with voting on director elections, auditor ratification, and executive compensation approval.
Shareholders of record as of April 20, 2026, are eligible to vote; proxy materials are primarily distributed electronically to reduce costs and environmental impact.
Board recommends voting FOR all proposals, including director nominees, auditor ratification, and executive compensation.
Voting matters and shareholder proposals
Three Class I directors (Stephen G. Dilly, Raymond De Vré, Rahul Singhvi) nominated for election to serve until 2029.
Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) for named executive officers.
Procedures for shareholder proposals and director nominations for future meetings outlined, with specific deadlines and requirements.
Board of directors and corporate governance
Board consists of nine directors divided into three classes with staggered three-year terms.
Board leadership structure separates Executive Chair and CEO roles; Lead Independent Director provides additional oversight.
All directors except the CEO and Executive Chair are independent under Nasdaq rules.
Five standing committees: audit, compensation, nominating and corporate governance, science and technology, and strategy.
Board and committees met regularly in 2025, with high attendance and active participation.
Board diversity and communication policies in place; code of business conduct and insider trading compliance program adopted.
Latest events from Codexis
- Q2 2026 saw $14.9M revenue, improved margins, and a $25M equity raise supporting future growth.CDXS
Q2 2026 - All proposals, including director elections and auditor ratification, were approved by stockholders.CDXS
AGM 2026 - ECO Synthesis enables scalable, sustainable RNA manufacturing, meeting surging siRNA demand.CDXS
Corporate presentation - Q1 2026 revenue doubled, net loss narrowed, and cash reserves support ongoing growth.CDXS
Q1 2026 - Key votes include director elections, auditor ratification, and executive pay approval.CDXS
Proxy filing - 2025 revenue up 19% to $70.4M, Q4 profitable, 2026 outlook strong with $72–76M guidance.CDXS
Q4 2025 - ECO Synthesis platform drives RNA medicine manufacturing growth, targeting a $2B market by 2030.CDXS
TD Cowen 46th Annual Health Care Conference - Enzymatic siRNA manufacturing platform targets major market growth, with breakeven eyed by 2026.CDXS
Stifel 2024 Healthcare Conference - Q2 revenue met expectations; guidance and double-digit growth outlook reaffirmed.CDXS
Q2 2024